Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.54 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL563577 | 0.78 | HCAR2 (0.47) | HCAR2CYP2C9CYP2C19PDPK1POLB | |
| SCHEMBL11333194 | 0.76 | PDPK1 (0.49) | PDPK1POLBESR1 | |
| SCHEMBL1914008 | 0.76 | PDPK1 (0.36) | HCAR2PDPK1 | |
| SCHEMBL11335310 | 0.75 | PDPK1 (0.55) | PDPK1 | |
| Hydrochloric Acid SCHEMBL27356432 | 0.73 | PDPK1 (0.54) | PDPK1 | |
| SCHEMBL7486774 | 0.72 | ESR1 (0.44) | PDPK1ESR1 | |
| SCHEMBL486309 | 0.72 | HCAR2 (1.00) | HCAR2SMYD3CYP2C9CYP2C19MKNK1 | |
| SCHEMBL29944817 | 0.72 | HCAR2 (1.00) | HCAR2SMYD3CYP2C9CYP2C19MKNK1 | |
| SCHEMBL28695687 | 0.70 | HCAR2 (0.96) | HCAR2SMYD3CYP2C9CYP2C19MKNK1 | |
| Hydrochloric Acid SCHEMBL10401123 | 0.70 | HCAR2 (0.96) | HCAR2SMYD3CYP2C9CYP2C19MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287338-A1 | Metalloproteinase inhibitor compounds | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287338-A1 | Metalloproteinase inhibitor compounds | TIMP3, MMP2, MMP13 | HCAR2 2624/4885SMYD3 2928/4885CYP2C9 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.